LONDON, November 27, 2013 /PRNewswire/ --
Edison Investment Research, a leading international
investment research firm, announces the initiation of coverage of
Mesoblast (MSB: ASX), an Australian-headquartered
biotechnology company focused on adult stem therapies.
(Logo:
http://photos.prnewswire.com/prnh/20130417/608168 )
Mesoblast's pipeline is based on its proprietary mesenchymal
precursor cell (MPC) and culture-expanded mesenchymal stem cell
(MSC) technologies. Edison's report, Precursor to success,
discusses Mesoblast's two technology platforms (MPCs and MSCs) that
have to date generated nine clinical candidates (four in Phase III,
five in Phase II). The report goes on to analyse the three
strategic partnerships with Teva, JCR and Lonza, which underpin the
key late-stage programmes including Revascor that could provide
US$4bn potential peak sales.
Edison's healthcare team value Mesoblast at A$2.6bn (A$8.07/share) based on a risk-adjusted net
present value (rNPV) analysis, which could rise to A$3.2bn (A$10.00/share) if upcoming catalysts are
positive.
For the full report see:
http://www.edisoninvestmentresearch.com/research/company/mesoblast
About Edison Investment Research
The launch of coverage on Mesoblast is part of a programme of
research initiations on biotechnology companies exposed to global
market opportunities. Edison provides detailed research coverage on
more than 150 pharmaceutical and healthcare companies in
Europe, North America, Australia and New
Zealand. Its team of over 100 analysts and investment
professionals works with leading companies, fund managers and
investment banks worldwide to support its capital markets activity.
It provides services to more than 400 retained corporate and
investor clients from offices in London, New
York, Frankfurt,
Sydney and Wellington. All reports Edison publishes are
available to download free of charge from its website
http://www.edisongroup.com.
Edison is authorised and regulated by the Financial Services
Authority
(http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).
Edison is not an adviser or broker-dealer and does not provide
investment advice. Edison's reports are not solicitations to buy or
sell any securities.
About Mesoblast
Mesoblast is developing adult stem cell therapies based on its
proprietary MPC and culture-expanded MSC platforms. It has six
late-stage clinical trials across four areas:
immunologic/inflammatory (Phase III), spine disease (Phase II),
cardiovascular (Phase III ready) and cancer (Phase III). The CVS
franchise, which is partnered with Teva, could enter Phase III for
heart failure in Q413. Worldwide manufacturing of MPCs will be
provided by Lonza.
For more information please
contact:
Dr Mike Aitkenhead, Edison
Investment Research, +44(0)20-3077-5736
healthcare@edisongroup.com
SOURCE Edison Investment Research
